Erasca Teams With Merck on AURORAS-1 Cancer Study
Published on 05/11/2026 at 08:12 am EDT
MT Newswires
Share
Share
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.27 USD | -1.04% |
|
+1.37% | +259.14% |
| Jun. 04 | Erasca Shares Rise After BofA Upgrade | MT |
| Jun. 04 | Erasca Sees More Balanced Outlook as Early RAS Data Support Clinical Activity, BofA Says | MT |
Employees
103
Trader
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
-
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
-
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
-
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
13.41USD
Average target price
21.00USD
Spread / Average Target
+56.60%
Quarterly revenue - Rate of surprise
- Stock Market
- Stock Market News
- Erasca Teams With Merck on AURORAS-1 Cancer Study
Select your edition
All financial news and data tailored to specific country editions
